← Leaderboards
Naoto T Ueno
University Of Texas Md Anderson Can Ctr
$18,288,723
Attributed
$20,497,430
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $7M · FY2007–25$10M$7.5M$5M$2.5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,528,325 · 12
By mechanism
R01$12,841,729 · 6
P30$9,555,716 · 3
C06$6,478,224 · 1
R21$381,216 · 1
K08$271,440 · 1
Top collaborators
- David Gallup4 shared
- Kyuson Yun4 shared
- Mikhail G Kolonin2 shared
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Funda Meric-Bernstam$12,297,463
- Xifeng Wu$28,679,533
- William H. Klein$13,225,229
- Roy S Herbst$12,300,874
- Mikhail G Kolonin$5,860,228
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorClinical TrialsPathway InteractionsBaseCellsMalignant Breast NeoplasmTranslatingCancer TherapyChemotherapyResponseEpidermal Growth Factor ReceptorCancer BiologyIn VivoMediatingResistanceSignal TransductionCancer CenterClinical ResearchDesignCombined Modality TherapyBreast Cancer PatientClinically RelevantCancer Patient
Grant awards (41)
University of Hawaii Cancer Center CCSG$2,191,000
P30 · FY2025 · CA · contact PI
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer$1,309,379
R01 · FY2025 · CA · contact PI
Validation of a novel 3D culture platform for TNBC treatment selection$1,198,662
R01 · FY2025 · CA
Developing a novel combination immunotherapy for triple-negative breast cancer$650,749
R01 · FY2025 · CA · contact PI
University of Hawaii Cancer Center CCSG$2,190,593
P30 · FY2024 · CA · contact PI
Developing a novel combination immunotherapy for triple-negative breast cancer$618,212
R01 · FY2024 · CA · contact PI
Validation of a novel 3D culture platform for TNBC treatment selection$583,104
R01 · FY2024 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer$541,958
R01 · FY2024 · CA · contact PI
Developmental Funds$306,124
P30 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$218,697
P30 · FY2024 · CA · contact PI
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer$192,495
R01 · FY2024 · CA · contact PI
University of Hawaii Cancer Center CCSG$187,303
P30 · FY2024 · CA · contact PI
University of Hawaii Cancer Center CCSG$2,191,000
P30 · FY2023 · CA · contact PI
Developing a novel combination immunotherapy for triple-negative breast cancer$664,874
R01 · FY2023 · CA · contact PI
Validation of a novel 3D culture platform for TNBC treatment selection$601,157
R01 · FY2023 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer$581,465
R01 · FY2023 · CA · contact PI
University of Hawaii Cancer Center CCSG$2,156,000
P30 · FY2022 · CA · contact PI
Validation of a novel 3D culture platform for TNBC treatment selection$644,226
R01 · FY2022 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer$536,764
R01 · FY2022 · CA · contact PI
University of Hawaii Cancer Center CCSG$114,999
P30 · FY2022 · CA · contact PI
Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer$366,000
R01 · FY2021 · CA · contact PI
Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer$366,000
R01 · FY2020 · CA · contact PI
Ho'ola: Early Phase Clinical Research Center$6,478,224
C06 · FY2019 · OD · contact PI
Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer$355,019
R01 · FY2019 · CA · contact PI
Adipose stromal cell targeting: a new approach to breast cancer treatment$198,737
R21 · FY2019 · CA
Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer$366,000
R01 · FY2018 · CA · contact PI
Adipose stromal cell targeting: a new approach to breast cancer treatment$182,479
R21 · FY2018 · CA
Enhancing anti-EGFR Therapeutic Efficacy in Inflammatory Breast Cancer$366,000
R01 · FY2017 · CA · contact PI
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer$252,379
R01 · FY2012 · CA · contact PI
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer$315,264
R01 · FY2011 · CA · contact PI
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer$283,822
R01 · FY2011 · CA · contact PI
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer$292,600
R01 · FY2010 · CA · contact PI
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer$292,600
R01 · FY2009 · CA · contact PI
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer$292,600
R01 · FY2009 · CA · contact PI
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer$292,600
R01 · FY2008 · CA · contact PI
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer$292,600
R01 · FY2008 · CA · contact PI
Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer$292,600
R01 · FY2007 · CA · contact PI
Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer$292,600
R01 · FY2007 · CA · contact PI
ADENOVIRUS E1A AS A THERAPEUTIC AGENT IN BREAST CANCER$90,480
K08 · FY2002 · CA
ADENOVIRUS E1A AS A THERAPEUTIC AGENT IN BREAST CANCER$90,480
K08 · FY2001 · CA
ADENOVIRUS E1A AS A THERAPEUTIC AGENT IN BREAST CANCER$90,480
K08 · FY2000 · CA